History of LTT Bio-Pharma
1980～
| Apr. 1988 | LTT Research Institute was established for the purpose of support of research and development of DDS-related technologies. |
|---|---|
| Jun. 1988 | Limethason®, a DDS product developed by LTT, was marketed by Mitsubishi Tanabe Pharma Corp. (former Green Cross Corp.). |
| July. 1988 | Haloart®, a DDS product developed by LTT, was marketed by Taiho Pharmaceutical Co., Ltd. |
| Oct. 1988 | Palux Injection®, a DDS product developed by LTT, was marketed by Taisho Pharmaceutical Co., Ltd. |
| Nov. 1988 | Liple Injection®, a DDS product developed by LTT, was marketed by Mitsubishi Tanalo Pharma Corp. A contract research agreement was concluded with St. Marianna University. |
1990～
| Oct. 1990 | Institute of Medical Science St. Marianna Univ. School of Medicine was established. |
|---|---|
| Jun. 1992 | Ropion Injection®, a DDS product developed by LTT, was marketed by Kaken Pharmaceutical Co., Ltd. |
| Mar. 1995 | Beijing Tide Pharmaceutical Co., Ltd. was established jointly with China-Japan Friendship Hospital, Beijing, China. Manufacturing of Lipo-PGE1 product was started in China with the technical support from Taisho Pharmaceutical Co., Ltd. |
| Apr. 1997 | The head office was moved to Nagata-cho, Chiyoda-ku, Tokyo. |
| Sep. 1998 | Farnezone and Farnerate were marketed by Taiho Pharmaceutical Co., Ltd. and Dainippon Sumitomo Pharmaceutical Co., Ltd., respectively. |
2000～
| Oct. 2001 | A contract research agreement was concluded with DDS Institute, Jikei University. |
|---|---|
| Nov. 2001 | The head office was moved to Atago, Minato-ku, Tokyo. |
| Jan. 2003 | LTT Bio-Pharma was founded by corporate separation from LTT Research Institute to transfer the pharmaceutical business. |
| Nov. 2004 | LTT Bio-Pharma was listed on TSE Mothers. |
| Jun. 2005 | Perfect Lift AA, a DDS product developed by LTT, was marketed by Rohto Pharmaceutical Co., Ltd. |
| Oct. 2005 | Sole Co., Ltd. (consolidated subsidiary) was established for the purpose of management of pharmacies. |
| Mar. 2006 | I&L Anti-Aging Management Co., Ltd. was established jointly for the purpose of support of anti-aging clinics. |
| Jun. 2006 | A joint enterprise agreement was concluded with Machine Parts Co., Ltd. for manufacturing and sales of MH punch. |
| Aug. 2006 | MH punch was marketed. |
| Nov. 2006 | An Early Phase Ⅱ clinical study of PC-SOD has been completed in Japan. This study showed that PC-SOD was effective for ulcerative colitis. |
| Dec. 2006 | LTT Bio-Pharma ties up with Cipla Ltd., India on Nanosteroids. |
| May. 2007 | A share exchange agreement was concluded to take over Asclepius Ltd. as a wholly-owned subsidiary of LTT Bio-Pharma. |
| Mar. 2008 | EIP punch which allows tableting without St-Mg was marketed. |
| Mar. 2008 | Asclepius Ltd. files for bankruptcy. |
| May. 2008 | Dr. Yutaka Mizushima passed away for heart failure. |
| Jun. 2008 | An Early Phase Ⅱ clinical study of PC-SOD has been completed in Japan. This study showed that PC-SOD was effective for idiopathic intersttial pheumonia. |
| Oct. 2008 | Machine Parts Marketing Co.,Ltd was established for the purpose of sales of EIP punch etc. |
| Feb. 2009 | The head office was moved to Kaigan,Minato-ku,Tokyo. |
| Feb. 2009 | LTT Bio Pharma Transferred Stocks of Sole Corporation. Deviate from consolidated companies. |
| Apr. 2009 | capital and business alliance agreement was concluded with Beijing Tide Pharmaceutical Co., Ltd. |
| Aug. 2009 | PC-SOD NE was adopted at NEDO(Government-subsidized projects) |
| Sep. 2009 | LTT-Bio Pharma had an exclusive license agreement (AS-013) with Beijing Tide Pharma at China. |
| Dec. 2009 | Toxicity study of PC-SOD NE was started. |
| Jan. 2010 | Ltt Bio Pharma made a collaborative research agreement(Stealth Type Nano-Particle Formulation) with Asahi Kasei Pharma corporation. It started basic research. |
| May. 2010 | Substance patent of PC-SOD granted in USA. |
| Jun. 2010 | PC-SOD designated an Orphan Drug by the Ministry of Health. |
| Jul. 2010 | Stealth Type Nano-Particle Formulation was adopted at NEDO(Government- subsidized projects) |
| Sep. 2010 | PhaseI study of PC-SOD NE was started. |
| Nov. 2010 | Addition of New Pipeline: Inducer of cancer stem cell differentiation (LT-0301) |
| Nov. 2010 | LTT-Bio Pharma had an exclusive license agreement with Beijing Tide Pharma on Stealth Type Nano-Particle Formulation. |
| Dec. 2010 | We started Repeated-dose study of PC-SOD(PhaseI study) on healthy volunteer. |
| Mar. 2011 | LTT Bio Pharma got out of EIP sales. |
| Apr. 2011 | LTT shares are now assigned a symbol indicating shares undergoing review for delisting. |
| Jul. 2011 | LTT shares have been put on a special list of shares due to be delisted. |
| Jul. 2011 | LTT-Bio Pharma had an exclusive license agreement with Chon Kun Dang Pharma Corp.(CKD) on PC-SOD NE. |
| Aug. 2011 | LTT Bio Pharma’s stocks will be delisting. (Aug 9. 2011) |
